May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Control of IOP in Open-Angle Glaucoma by Anecortave Acetate: A Comparison of Three Doses and Vehicle
Author Affiliations & Notes
  • E. R. Craven
    Glaucoma Consultants of Colorado, Littleton, Colorado
  • A. L. Robin
    Johns Hopkins University School of Medicine, Baltimore, Maryland
  • R. M. Feldman
    Department of Ophthalmology, University of Texas At Houston Medical School, Houston, Texas
  • S. A. Scheib
    Alcon Research, Ltd, Fort Worth, Texas
  • J. E. Dickerson
    Alcon Research, Ltd, Fort Worth, Texas
  • T. A. Landry
    Alcon Research, Ltd, Fort Worth, Texas
  • D. T. Wells
    Alcon Research, Ltd, Fort Worth, Texas
  • A. F. Clark
    Alcon Research, Ltd, Fort Worth, Texas
  • M. V. W. Bergamini
    Alcon Research, Ltd, Fort Worth, Texas
  • Footnotes
    Commercial Relationships  E.R. Craven, Alcon, F; A.L. Robin, Alcon, F; R.M. Feldman, Alcon, F; S.A. Scheib, Alcon, E; J.E. Dickerson, Alcon, E; T.A. Landry, Alcon, E; D.T. Wells, Alcon, E; A.F. Clark, Alcon, E; M.V.W. Bergamini, Alcon, E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1207. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. R. Craven, A. L. Robin, R. M. Feldman, S. A. Scheib, J. E. Dickerson, T. A. Landry, D. T. Wells, A. F. Clark, M. V. W. Bergamini; Control of IOP in Open-Angle Glaucoma by Anecortave Acetate: A Comparison of Three Doses and Vehicle. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1207. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the safety and intraocular pressure (IOP)-lowering efficacy of anecortave acetate (AA) ophthalmic suspension (3, 15, and 30 mg) compared to vehicle, administered as a single anterior juxtascleral depot (AJD) in patients with a clinical diagnosis of open-angle glaucoma (OAG).

Methods: : This was a randomized double-masked multi-center (N=10) study. Eligible patients had a clinical diagnosis of OAG and eligibility IOP between 24 and 36 mmHg in the study eye. Qualifying patients were randomized to receive a single 0.5 mL AJD of anecortave acetate (3, 15, or 30 mg) or vehicle in the "worse" eye. The fellow, non-injected eye was treated with latanoprost. On-therapy visits were at 2, 6 and 12 weeks. Success was defined as an IOP 21 mmHg.

Results: : 85 of 86 patients were evaluable by ITT. 42% of the patients were on multiple IOP-lowering medications prior to the study. Mean baseline IOP was similar across all four treatment groups for both eyes (range=27.1 to 28.3 mmHg, injected eye; 22.8 to 25.5 mmHg, fellow eye). At 3 months, the success rate (IOP 21 mmHg) was similar for the 3 and 15 mg groups (approximately 30%) and was 50% for the 30 mg group. This was about two-fold that seen for the vehicle group (24%). Patients considered treatment successes had similar mean IOP reductions in the study eye (regardless of dose) of -8, -6.7, and -7 mmHg for 3, 15, and 30 mg, respectively, compared to -1.4 mmHg for the vehicle treated group. Interestingly, mean IOP reductions for the latanoprost-treated fellow eyes ranged between -5 and -7 mmHg depending on the treatment group. The most common adverse events were eye pain, foreign body sensation, and blurred vision. Of the 14 reports of eye pain, 9 (64%) were related to the injection procedure.

Keywords: vascular endothelial growth factor • injection • intraocular pressure 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.